Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

Douxfils, Jonathan;Mullier, François;Loosen, Claire;Chatelain, Christian;Dogné, Jean-Michel;et.al.
(2012) Thrombosis Research : vascular obstruction, hemorrhage and hemostasis — Vol. 130, n° 6, p. 956-966 (2012)

Files

DouxfilsJ-ThrombRes-2012.pdf
  • Restricted Access
  • Adobe PDF
  • 819.99 KB
Request a copy

Details

Authors
  • Douxfils, Jonathan
    Author
  • Mullier, FrançoisUCLouvain
    Author
  • Loosen, Claire
    Author
  • Chatelain, ChristianUCLouvain
    Author
  • Chatelain, BernardUCLouvain
    Author
  • Dogné, Jean-Michel
    Author
Show more
Abstract
PT may be used as screening test to assess the risk of bleedings. A more specific and sensitive assay such as Biophen DiXaI using calibrators should be used to confirm the concentration of rivaroxaban. We also propose cut-off associated with a bleeding or thrombosis risk based on pharmacokinetic studies. Standardization of the time between the last intake of rivaroxaban and the sampling is mandatory.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Douxfils, J., Mullier, F., Loosen, C., Chatelain, C., Chatelain, B., & Dogné, J.-M. (2012). Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thrombosis Research : vascular obstruction, hemorrhage and hemostasis, 130(6), 956-966. https://doi.org/10.1016/j.thromres.2012.09.004 (Original work published 2012)